Gene · 90427
BMF: Bcl2 modifying factor
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. BMF: Bcl2 modifying factor. Genes, record 90427. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/90427
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q96LC9 | Bcl-2-modifying factor | 184 | 5 | Ensembl, GeneID, HGNC |
Source UniProt
Patents54
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 38695 | Q96LC9 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 38696 | Q96LC9 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 38701 | Q96LC9 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 38702 | Q96LC9 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 5224 | Q96LC9 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 8520 | Q96LC9 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 8521 | Q96LC9 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 8524 | Q96LC9 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 8525 | Q96LC9 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 5224 | Q96LC9 | Espacenet |
1 to 10 of 54
See all 54 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,100
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | BMF papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 15 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 9 | 2025 |
| P30CA056036 | Translational Research in Cancer | 7 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 7 | 2025 |
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | 6 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 6 | 2025 |
| P01CA066996 | Development of Novel Therapeutic Strategies in Human Leukemias | 5 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 5 | 2025 |
| P30CA013696 | Cancer Center Support Grant | 3 | 2025 |
| P30CA014520 | UW Comprehensive Cancer Center Support | 3 | 2025 |
1 to 10 of 1,100Source NIH's project files
See all 1,100 nih grantsPapers1,838
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Glucocorticoid receptor activation reorganizes Wnt/LEF1 regulatory circuitry associated with therapeutic response in B-cell acute lymphoblastic leukemia. | bioRxiv | 2026 | 42818321 | PubTator, text mining | PubMed |
| Identification of Inflammatory Cell Death-Related Prognostic Signature and Its Regulatory Mechanism in Lung Adenocarcinoma. | Cancer Med | 2026 | 42760759 | PubTator, text mining | PubMed |
| Comprehensive bioinformatic analyses identify a PANoptosome-related gene diagnostic signature in keloid fibroblasts. | Burns | 2026 | 42607510 | PubTator, text mining | PubMed |
| Apoptotic Signaling Across Breast Cancer Subtypes and Cryoablation-Induced Tissue Injury. | Int J Mol Sci | 2026 | 42352901 | PubTator, text mining | PubMed |
| Oxidative stress-preconditioned exosomes target BMF to restore mitophagy for alleviating intervertebral disc degeneration. | Autophagy | 2026 | 42329074 | PubTator, text mining | PubMed |
| ATRX loss in sarcomas is associated with dysregulated gene and transposable element expression, loss of DNA methylation, and worse survival. | ESMO Rare Cancers | 2026 | 41994103 | PubTator, text mining | PubMed |
| Targeting BCL-xL in Myeloid Malignancies: From Inhibitors to PROTAC. | J Cell Mol Med | 2026 | 41937490 | PubTator, text mining | PubMed |
| Recurrence of focal segmental glomerulosclerosis: An updated review of pathophysiology, biomarkers, and therapeutic strategies. | Cell Transplant | 2026 | 41906863 | PubTator, text mining | PubMed |
| BMP4-driven morphogenetic reprogramming sustains EGFR-TKI resistance via SOX2 suppression and EMT activation. | Biomed Pharmacother | 2026 | 41904893 | PubTator, text mining | PubMed |
| Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications. | Signal Transduct Target Ther | 2026 | 41881983 | PubTator, text mining | PubMed |
1 to 10 of 1,838
See all 1,838 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/90427
GET https://conductscience.org/api/genes/v1/90427/patents?page=2